Literature DB >> 11858774

Familial Hypercholesterolemia.

Paul N. Hopkins1.   

Abstract

Heterozygous familial hypercholesterolemia is a common, severe form of elevated plasma, low-density lipoprotein (LDL) cholesterol. Familial hypercholesterolemia is under-recognized and under-treated despite well-known benefits from available lipid-lowering medications. To help address these problems, the humanitarian MEDPED (Make Early Diagnoses, Prevent Early Deaths) organization was developed as a means to find and help persons with familial hypercholesterolemia all over the world. Although some patients with familial hypercholesterolemia can be treated adequately with a statin alone, many require aggressive treatment with a combination of drugs, including a statin, bile acid sequestrant, and niacin to reach LDL goals. Such treatment has resulted in regression of angiographically monitored coronary lesions in patients with familial hypercholesterolemia.

Entities:  

Year:  2002        PMID: 11858774     DOI: 10.1007/s11936-002-0032-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  35 in total

1.  Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor.

Authors:  K Oka; L Pastore; I H Kim; A Merched; S Nomura; H J Lee; M Merched-Sauvage; C Arden-Riley; B Lee; M Finegold; A Beaudet; L Chan
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

2.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08

3.  Effect of soy protein diet versus standard low fat, low cholesterol diet on lipid and lipoprotein levels in children with familial or polygenic hypercholesterolemia.

Authors:  K Widhalm; G Brazda; B Schneider; S Kohl
Journal:  J Pediatr       Date:  1993-07       Impact factor: 4.406

4.  Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications.

Authors:  L Goldman; P A Goldman; L W Williams; M C Weinstein
Journal:  Am J Cardiol       Date:  1993-09-30       Impact factor: 2.778

5.  Dietary treatment for familial hypercholesterolemia--differential effects of dietary soy protein according to the apolipoprotein E phenotypes.

Authors:  A Gaddi; A Ciarrocchi; A Matteucci; S Rimondi; G Ravaglia; G C Descovich; C R Sirtori
Journal:  Am J Clin Nutr       Date:  1991-05       Impact factor: 7.045

6.  Familial hypercholesterolemia and familial defective apolipoprotein B-100: comparison of the phenotypic expression In 116 cases.

Authors:  D Brugger; H Schuster; N Zöllner
Journal:  Eur J Med Res       Date:  1996-05-24       Impact factor: 2.175

7.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

8.  Effects of n-3 and n-6 fatty acid-enriched diets on plasma lipoproteins and apolipoproteins in heterozygous familial hypercholesterolemia.

Authors:  K E Friday; R A Failor; M T Childs; E L Bierman
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb

9.  A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.

Authors:  M Grossman; D J Rader; D W Muller; D M Kolansky; K Kozarsky; B J Clark; E A Stein; P J Lupien; H B Brewer; S E Raper
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

10.  Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.

Authors:  E Leitersdorf; E N Muratti; O Eliav; T K Peters
Journal:  Am J Cardiol       Date:  1995-07-13       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.